Development of 177Lu-phytate Complex for Radiosynovectomy
نویسندگان
1 Radiopharmaceutical Research and Development Lab, Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran, P.O.Box:14395-836
2 Radiopharmaceutical Research and Development Lab, Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran, P.O.Box:14395-836
3 Radiopharmaceutical Research and Development Lab, Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran, P.O.Box:14395-836 2 Faculty of Energy Engineering and Physics, Amirkabir University of Technology. Tehran, Iran
4 Radiopharmaceutical Research and Development Lab, Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran, P.O.Box:14395-836
5 Radiopharmaceutical Research and Development Lab, Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran, P.O.Box:14395-836
6 Radiation Application Group, Faculty of Nuclear Engineering, Shahid Beheshti University, Tehran, Iran
doi
10.22038/ijbms.2013.784چکیده
Objective(s): In this work a new possible agent for radiosynovectomy has been targeted for articular pain palliation. Materials and Methods: Lu-177 of 2.6-3 GBq/mg specific activity was obtained by irradiation of natural Lu2O3 sample with thermal neutron flux of 4 × 1013 n.cm-2.s-1. The product was converted into chloride form which was further used for labeling of 177Lu-phytate complex and checked using ITLC (MeOH: H2O: acetic acid, 4: 4: 2, as mobile phase). The complex stability and viscosity were checked in the final solution up to seven days. The prepared complex solution (100 µCi/100 µl) was injected intra-articularly to male rat knee joint. Leakage of radioactivity from injection site and its distribution in organs were investigated up to seven days. Results: The complex was successfully prepared with high radiochemical purity (>99.9 %). Approximately, the whole injected dose has remained in injection site seven days after injection. Conclusion: The complex was proved to be a feasible agent for cavital radiotherapy in oncology and rheumatology
